Pfizer in 2005
|
|
ICMR HOME | Case Studies Collection
Case Details:
Case Code : BSTA120
Case Length : 15 Pages
Period : 1849-2005
Organization : -
Pub Date : 2005
Teaching Note :Not Available
Countries : USA
Industry : Pharmaceuticals
To download Pfizer in 2005 case study (Case Code: BSTA120) click on the button below, and select the case from the list of available cases:
Price:
For delivery in electronic format: Rs. 300;
For delivery through courier (within India): Rs.
300 + Rs. 25 for Shipping & Handling Charges
» Business Strategy Case Studies
» Case Studies Collection
» Business Strategy Short Case Studies
» View Detailed Pricing Info
» How To Order This Case
» Business Case Studies
» Area Specific Case Studies
» Industry Wise Case Studies
» Company Wise Case Studies
Please note:
This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.
|
|
<< Previous
Introduction
|
The world's largest research-based pharmaceuticals firm, Pfizer was well known for its blockbuster drugs such as the pain management drug Celebrex, antidepressant Zoloft, erectile dysfunction therapy Viagra, and cholesterol-lowering Lipitor.
In addition to prescription drugs, the company made OTC (Over The Counter) remedies, including Benadryl and Sudafed, treatments for common cold. In 2005, Pfizer had ten drugs topping a billion dollars in sales, including Lipitor ($10.9 billion), Norvasc, a therapy for high blood pressure ($4.5 billion), Zoloft ($3.4 billion), Celebrex
($3.3 billion), and Viagra ($1.7 billion).
|
|
Those ten drugs together accounted for nearly 70% of the
company's human health segment sales. Pfizer's largest customers were the three top drug distributors in the US, McKesson, which accounted for 18% of Pfizer's sales in 2004, Cardinal Health (14%), and AmerisourceBergen (13%). Pfizer generated almost 45% of its 2004 sales in the US. Japan was its second-largest market, accounting for 6% of sales.
As 2005 got underway, the major concern for Pfizer was patent expiration. The company had warned investors it would probably lose some $14 billion due to patent expirations by 2007. Meanwhile, the company was spending heavily on cancer-research. Pfizer was also moving in a direction that would pit it against biotech companies such as Onyx, Genentech etc. Would Pfizer be able to find alternative sources of revenue? Would Pfizer's forays into biotech succeed?...
Excerpts >>
|
|
